Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma

Neurofibromatosis type 2 (NF2) causes bilateral vestibular schwannomas (VSs), leading to deafness. VS is treated by surgery or radiation, but neither treatments prevent hearing loss. Bevacizumab was found to be effective in suppressing the tumor’s growth and may help to improve hearing. We are condu...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Masazumi Fujii, Masao Kobayakawa, Kiyoshi Saito, Akihiro Inano, Akio Morita, Mitsuhiro Hasegawa, Akitake Mukasa, Takafumi Mitsuhara, Takeo Goto, Shigeru Yamaguchi, Takashi Tamiya, Hirofumi Nakatomi, Soichi Oya, Fumiaki Takahashi, Taku Sato, Mudathir Bakhit, on behalf of the BeatNF2 Trial Investigators
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-01-01
Colecção:	Current Oncology
Assuntos:	neurofibromatosis type 2 schwannoma bevacizumab clinical trial
Acesso em linha:	https://www.mdpi.com/1718-7729/28/1/71
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!